Bayer to appeal $2 billion glyphosate-cancer verdict with EPA Roundup assessment excluded from trial

Bayer plans to make the EPA’s safety endorsement of a chemical in Roundup central to its case as the company fights claims its weedkiller causes cancer.

In recent months, Bayer has been handed three jury verdicts ordering the company to pay more than $2 billion in damages to plaintiffs who believe exposure to Roundup caused their non-Hodgkin lymphoma ….

…. In April, the EPA released a draft risk assessment stating glyphosate is not a carcinogen …. a conclusion the agency has consistently made as it periodically reviews the herbicide. Attorneys for Bayer tried to introduce that evidence during the third trial …. but were rebuffed by the judge.

Related on the SLP

New Zealand scientist challenges ‘scaremongering’ about herbicide glyphosate Roundup litigation reprieve? U.S. government backs Bayer’s claim that its glyphosate is safe-as-used finding preempts random, conflicting state-by-state ‘failure-to-warn’ claims

As Europe inches forward in its embrace of gene-edited crops, hopes abound that opposition to GMOs might fade

Drugs and supplements can extend life and five other longevity myths

World Health Organization calls Kennedy- and CDC-backed Guinea-Bissau hepatitis B vaccine study designed to ‘prove’ the danger of vaccines “unethical”

Defense attorneys plan to make that judge’s ruling a key part of their attempt to overturn the third jury verdict during appeal

Read full, original article: Bayer to lean on EPA review of glyphosate in court battles (Behind Paywall)